Shares of Icon Plc (NASDAQ:ICLR) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $159.18.

A number of research analysts recently commented on the company. Jefferies Financial Group decreased their price objective on Icon from $180.00 to $146.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Citigroup decreased their price objective on Icon from $185.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Credit Suisse Group decreased their price objective on Icon from $187.00 to $181.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. Wells Fargo & Co decreased their price objective on Icon from $180.00 to $140.00 and set an “equal weight” rating on the stock in a report on Monday, March 30th. Finally, Mizuho decreased their price objective on Icon from $180.00 to $154.00 and set a “buy” rating on the stock in a report on Friday, April 3rd.

Shares of Icon stock traded up $4.07 on Friday, hitting $166.56. 3,154 shares of the company were exchanged, compared to its average volume of 237,384. The stock has a market capitalization of $8.57 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 3.40 and a beta of 0.86. The company has a 50-day moving average price of $162.25 and a 200 day moving average price of $160.15. Icon has a 1-year low of $104.28 and a 1-year high of $178.99. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.05.

Icon (NASDAQ:ICLR) last issued its earnings results on Wednesday, April 22nd. The medical research company reported $1.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.02. The business had revenue of $715.10 million for the quarter, compared to analysts’ expectations of $711.07 million. Icon had a return on equity of 24.20% and a net margin of 13.26%. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.63 EPS. Research analysts forecast that Icon will post 5.71 EPS for the current year.

Several institutional investors have recently bought and sold shares of ICLR. Norges Bank purchased a new stake in shares of Icon during the fourth quarter worth $101,406,000. Comgest Global Investors S.A.S. increased its position in shares of Icon by 15.5% during the fourth quarter. Comgest Global Investors S.A.S. now owns 1,760,847 shares of the medical research company’s stock worth $303,270,000 after acquiring an additional 235,944 shares during the period. Invesco Ltd. increased its position in shares of Icon by 15.8% during the first quarter. Invesco Ltd. now owns 1,605,497 shares of the medical research company’s stock worth $218,347,000 after acquiring an additional 218,782 shares during the period. Zurich Insurance Group Ltd FI increased its position in shares of Icon by 139.7% during the first quarter. Zurich Insurance Group Ltd FI now owns 359,307 shares of the medical research company’s stock worth $48,866,000 after acquiring an additional 209,407 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Icon by 14.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,590,967 shares of the medical research company’s stock worth $274,011,000 after acquiring an additional 199,267 shares during the period. 82.71% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: What is Elliott Wave theory?

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.